Massachusetts General Hospital Researchers and Prevencio Announce the Power of Artificial Intelligence HART Platform

AI-driven HART platform has produced seven highly accurate multiple protein blood tests presented in 32 peer-reviewed manuscripts and presentations

Prevencio, the AI-Powered Cardiac Blood Test Company, announces the culminative presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART blood tests are highly accurate in a broad range of patients, including those suffering from diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic and may be used to develop diagnostics beyond cardiac disease.

AiThority Interview Insights: How to Get Started with Prompt Engineering in Generative AI Projects

“Based on our AI-based diagnostic development expertise, Seattle Children’s Hospital and Research Institute solicited Prevencio to use our HART platform to develop and commercialize a diagnostic for Kawasaki disease, a childhood disease in which there was no commercially available diagnostic”

Prevencio’s two lead tests, HART CVE and HART CADhs, are currently available to medical professionals for patient use. HART CVE determines a patient’s short-to-intermediate risk for a heart attack, stroke, or cardiovascular death, while HART CADhs assesses whether a patient has obstruction of the heart arteries and is at imminent risk of a heart attack.

Read More about AiThority Interview: AiThority Interview with Bill Patterson, EVP and General Manager, Applications at Salesforce

Researchers from Massachusetts General Hospital (MGH) tested more than 1,250 patients undergoing coronary or peripheral angiography to collaborate in the development and validation of the AI-driven HART platform which has produced seven highly accurate, algorithmic multiple protein blood tests.

“It is impressive the HART tests provide robust accuracy amongst a wide range of patients,” said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Director of Biomarker Trials at the Baim Institute for Clinical Research, and Principal Investigator in development, validation, and ongoing testing of six of the seven HART tests. “With the rapid rise in cardiovascular disease, better tools to recognize risk and intervene proactively are needed. Our data suggest that AI-derived, multi-protein, algorithmically scored blood tests may be useful to individualize cardiac risk assessment and foster aggressive primary and secondary cardiovascular prevention. We are especially excited with our most recent data demonstrating the accuracy of HART CVE in assessing risk in patients with total chronic occlusion of the coronary arteries and look forward to using the HART platform to develop additional clinical applications and diagnostic tests.”

“Based on our AI-based diagnostic development expertise, Seattle Children’s Hospital and Research Institute solicited Prevencio to use our HART platform to develop and commercialize a diagnostic for Kawasaki disease, a childhood disease in which there was no commercially available diagnostic,” stated Rhonda Rhyne, Prevencio’s President and Chief Executive Officer. “The company has also been engaged by leading cancer centers and global companies to use the HART platform and HART tests for assessing patient risk, efficacy of treatments, and development of diagnostics and other devices.”

Prevencio will host a press conference to showcase our leading-edge, AI-powered HART platform and blood tests at the American Association of Clinical Chemistry Annual Meeting at the Anaheim Convention Center on July 25, 2023, at 2pm PDT in Room 213C. For one-on-one meetings, please contact us at (425) 576-1200.

 Latest AiThority Interview Insights : AiThority Interview with Michael Schmidt, Chief Technology Officer at DataRobot

 [To share your insights with us, please write to sghosh@martechseries.com]